WO1999047174A1 - Amorphous glasses for stabilising sensitive products - Google Patents
Amorphous glasses for stabilising sensitive products Download PDFInfo
- Publication number
- WO1999047174A1 WO1999047174A1 PCT/GB1999/000820 GB9900820W WO9947174A1 WO 1999047174 A1 WO1999047174 A1 WO 1999047174A1 GB 9900820 W GB9900820 W GB 9900820W WO 9947174 A1 WO9947174 A1 WO 9947174A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mannitol
- drying
- glass
- compound
- inositol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- trehalose Because it is subsequently degraded in the body by the specific enzyme, trehalase, to two molecules of glucose, trehalose possesses many of the properties of the ideal industrial stabiliser for foods and medical products.
- a large scientific and patent literature has now developed on trehalose stabilisation of foods, vaccines, diagnostics and drugs.
- the disadvantages of trehalose are that it is as yet not approved by the regulatory authorities, it is expensive and it contains contaminating reducing sugars, especially glucose, in all but the most rigorously purified material.
- the effect of these substances is dose dependent and below a threshold concentration they do not work.
- the substances useful in accordance with this invention promote the drying of mannitol solutions as glasses rather than crystals.
- One of the most potent materials is the borate ion either as boric acid, or tetraborate salts of sodium or potassium. This probably forms a network complex with mannitol or even a covalent compound, sodium mannitoborate.
- the quality of the glasses made by this process is high.
- the glass transition temperature (Tg) of 1 :1 w/w mannitol/calcium lactate glass is around 68°C ( Figure 1). This compares with a Tg of around 90°C for a trehalose/sodium sulphate glass dried under the same conditions ( Figure 2). Both types of glass have Tg's well above any possible ambient storage temperature and, because the glasses are chemically inert and non-reactive, the entrapped products are stable at room temperatures and require no refrigeration of any kind.
- Figure 1 shows differential scanning calorimetry of a 50 / 50 w/w mannitol / calcium lactate glass showing a clear glass transition at a temperature of 68 °C;
- Figure 2 shows differential scanning calorimetry of a 50 / 50 w/w trehalose / calcium lactate glass showing a clear glass transition at a temperature of 90 °C;
- Figure 3 shows the percentage recovery of alkaline phosphatase activity after vacuum- drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 6 weeks. There is no loss with formula 7 but serious losses with trehalose;
- Figure 4 shows the percentage recovery of alkaline phosphatase activity after freeze-drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 7 weeks. There is little loss with either stabiliser;
- Figure 5 shows the percentage recovery of Erythropoietin (EPO) after vacuum-drying in either trehalose or formula 8 containing mannitol, inositol, galactitol and calcium lactate followed by storage at 37°C or 50°C for up to 6 weeks. While there is serious losses with trehalose, no loss occurs with formula 8; and
- Figure 6 shows the percentage recovery of EPO after freeze-drying in either trehalose or formula 7 containing mannitol, Inositol, galactitol and degraded gelatin (Byco C) or formula 8 in which calcium lactate was substituted for the gelatin. After storage at 37°C or 50°C for 7 weeks, there is no loss with any of the stabilising formulations.
- Figure 7 shows the percentage recovery of alkaline phosphatase activity after spray drying formula 9 to which had been added insoluble calcium phosphate powder to increase the density of the glass microspheres. After storage at either 37°C or 55°C for up to 90 days there was no significant loss of activity.
- Figure 8 shows the percentage recovery alkaline phosphatase activity after spray drying formula 1 1 to which had been added insoluble barium sulphate powder to increase the density of the glass microspheres. After storage at either 37"C or 55°C for up to 90 days there was again no significant loss of activity.
- a network forming additive such as sodium or potassium tetraborate
- a network forming additive such as sodium or potassium tetraborate
- Affinity purified alkaline phosphatase from bovme intestinal mucosa (Sigma Chemical Co cat No p-8647) was vacuum-d ⁇ ed or freeze-d ⁇ ed m 200 ⁇ l volumes in formulation Number 7 above or in trehalose.
- Vacuum drying was done at a shelf temperature of 40°C and a vacuum of 30- 100 milhtorr for 4 hr The temperature was then ramped gradually to 60°C over 1 hr and the vials were stoppered and removed from the vacuum chamber for high temperature storage trials Freeze-drying was done in a Labconco dryer at an initial shelf temperature of-40°C for 3 hr at a vacuum of 30-100 milhtorr The shelf temperature was then ramped to 0°C at 5°C / mm and held for 1 hr The shelf temperature was then raised to 40°C at 5°C / min and secondary drying was continued for a further 3 hr when the vials were stoppered under vacuum and removed for storage trials
- EPO was vacuum dried or freeze-d ⁇ ed as above in the same solutions and also in a va ⁇ ant of formulation 7 in which calcium lactate was substituted for Byco C (Formula 8), and then subjected to the same stability tests before being assayed by a standard 2-s ⁇ te sandwich Enzyme Immunoassay
- the fluorescent protein R-Phycoeryth ⁇ n was air-dried in trehalose, formula 3 or formula 4 on a hotplate as described in Example 1
- the intensity of fluorescence was gauged visually when illuminated with a UV lamp.
- the material dried in formula 3 was masked by an intense silver autofluorescence from the Byco C while the material dried in formula 4 fluoresced with the characteristic orange colour with apparently undimmished intensity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99910516A EP1071465A1 (en) | 1998-03-18 | 1999-03-17 | Amorphous glasses for stabilising sensitive products |
| AU29451/99A AU2945199A (en) | 1998-03-18 | 1999-03-17 | Amorphous glasses for stabilising sensitive products |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9805699.7A GB9805699D0 (en) | 1998-03-18 | 1998-03-18 | New stabilising glasses |
| GB9805699.7 | 1998-03-18 | ||
| GBGB9820689.9A GB9820689D0 (en) | 1998-09-23 | 1998-09-23 | New stabilising glasses |
| GB9820689.9 | 1998-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999047174A1 true WO1999047174A1 (en) | 1999-09-23 |
Family
ID=26313295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1999/000820 Ceased WO1999047174A1 (en) | 1998-03-18 | 1999-03-17 | Amorphous glasses for stabilising sensitive products |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1071465A1 (en) |
| AU (1) | AU2945199A (en) |
| WO (1) | WO1999047174A1 (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190701B1 (en) | 1999-03-17 | 2001-02-20 | Peter M. Ronai | Composition and method for stable injectable liquids |
| WO2001089313A1 (en) * | 2000-05-26 | 2001-11-29 | British Sugar Plc | Edible products with coatings comprising amorphous trehalose |
| US6623762B2 (en) | 2001-02-16 | 2003-09-23 | Cambridge Biostability Ltd. | Composition and method for controlled release injections |
| US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
| EP1449523A1 (en) * | 2000-10-13 | 2004-08-25 | Cambridge Biostability Ltd | Composition and method for stable injectable liquids |
| US20080294100A1 (en) * | 2005-11-21 | 2008-11-27 | Cambridge Biostability Limited | Pharmaceutical Device For the Administration of Substrates to Patients |
| EP2290366A1 (en) | 2004-03-17 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Analysis of saccharide vaccines without interference |
| WO2011048379A2 (en) | 2009-10-21 | 2011-04-28 | Innovata Limited | Composition |
| CN107340387A (en) * | 2017-06-20 | 2017-11-10 | 广东云天抗体生物科技有限公司 | A kind of preparation method of cell factor ELISA standard items |
| IT201900025063A1 (en) * | 2019-12-20 | 2021-06-20 | Idi Integratori Dietetici Italiani S R L | GASTRORESISTANT COMPOSITIONS INCLUDING INOSITOL AND / OR SYLVESTRE GYMNEMA EXTRACT, THEIR PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS AND THEIR USE |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112538111B (en) * | 2020-12-09 | 2022-04-29 | 深圳市亚辉龙生物科技股份有限公司 | Novel coronavirus single chain antibody, quality control product and preparation method |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806524A (en) * | 1984-10-18 | 1989-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stable erythropoietin preparation and process for formulating the same |
| EP0682944A1 (en) * | 1994-05-04 | 1995-11-22 | Sanofi | Stable lyophilized formulation containing a protein and dosage kit |
| WO1996005809A1 (en) * | 1994-08-19 | 1996-02-29 | Quadrant Holdings Cambridge Limited | Improved method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
| WO1996040077A2 (en) * | 1995-06-07 | 1996-12-19 | Quadrant Holdings Cambridge Limited | Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby |
| US5589167A (en) * | 1993-02-23 | 1996-12-31 | Genentech, Inc. | Excipient stabilization of polypeptides treated with organic solvents |
| US5621094A (en) * | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
| WO1998041188A2 (en) * | 1997-03-18 | 1998-09-24 | Quadrant Holdings Cambridge Limited | Stable particle in liquid formulations |
-
1999
- 1999-03-17 AU AU29451/99A patent/AU2945199A/en not_active Abandoned
- 1999-03-17 EP EP99910516A patent/EP1071465A1/en not_active Withdrawn
- 1999-03-17 WO PCT/GB1999/000820 patent/WO1999047174A1/en not_active Ceased
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806524A (en) * | 1984-10-18 | 1989-02-21 | Chugai Seiyaku Kabushiki Kaisha | Stable erythropoietin preparation and process for formulating the same |
| US5621094A (en) * | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
| US5589167A (en) * | 1993-02-23 | 1996-12-31 | Genentech, Inc. | Excipient stabilization of polypeptides treated with organic solvents |
| EP0682944A1 (en) * | 1994-05-04 | 1995-11-22 | Sanofi | Stable lyophilized formulation containing a protein and dosage kit |
| WO1996005809A1 (en) * | 1994-08-19 | 1996-02-29 | Quadrant Holdings Cambridge Limited | Improved method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
| WO1996040077A2 (en) * | 1995-06-07 | 1996-12-19 | Quadrant Holdings Cambridge Limited | Methods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby |
| WO1998041188A2 (en) * | 1997-03-18 | 1998-09-24 | Quadrant Holdings Cambridge Limited | Stable particle in liquid formulations |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190701B1 (en) | 1999-03-17 | 2001-02-20 | Peter M. Ronai | Composition and method for stable injectable liquids |
| WO2001089313A1 (en) * | 2000-05-26 | 2001-11-29 | British Sugar Plc | Edible products with coatings comprising amorphous trehalose |
| US6919172B2 (en) | 2000-07-26 | 2005-07-19 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
| US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
| EP1449523A1 (en) * | 2000-10-13 | 2004-08-25 | Cambridge Biostability Ltd | Composition and method for stable injectable liquids |
| EP1452171A3 (en) * | 2000-10-13 | 2004-11-10 | Cambridge Biostability Ltd | Pharmaceutical liquid suspensions |
| US6623762B2 (en) | 2001-02-16 | 2003-09-23 | Cambridge Biostability Ltd. | Composition and method for controlled release injections |
| KR100852389B1 (en) | 2001-02-16 | 2008-08-14 | 캠브리지 바이오스테빌리티 리미티드 | Composition and method for controlled release injections |
| EP2290366A1 (en) | 2004-03-17 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Analysis of saccharide vaccines without interference |
| US20080294100A1 (en) * | 2005-11-21 | 2008-11-27 | Cambridge Biostability Limited | Pharmaceutical Device For the Administration of Substrates to Patients |
| US8821437B2 (en) * | 2005-11-21 | 2014-09-02 | Nova Bio-Pharma Technologies Limited | Pharmaceutical device for the administration of substances to patients |
| WO2011048379A2 (en) | 2009-10-21 | 2011-04-28 | Innovata Limited | Composition |
| CN107340387A (en) * | 2017-06-20 | 2017-11-10 | 广东云天抗体生物科技有限公司 | A kind of preparation method of cell factor ELISA standard items |
| IT201900025063A1 (en) * | 2019-12-20 | 2021-06-20 | Idi Integratori Dietetici Italiani S R L | GASTRORESISTANT COMPOSITIONS INCLUDING INOSITOL AND / OR SYLVESTRE GYMNEMA EXTRACT, THEIR PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS AND THEIR USE |
| WO2021124244A1 (en) * | 2019-12-20 | 2021-06-24 | Idi Integratori Dietetici Italiani S.R.L. | Gastro-resistant microparticles comprising inositol and/or gymnema sylvestre extract, pharmaceutical and nutraceutical compositions thereof and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1071465A1 (en) | 2001-01-31 |
| AU2945199A (en) | 1999-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100777349B1 (en) | Preservation of sensitive biological material | |
| Izutsu et al. | Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices | |
| Izutsu et al. | Decreased protein-stabilizing effects of cryoprotectants due to crystallization | |
| EP1071465A1 (en) | Amorphous glasses for stabilising sensitive products | |
| US6669963B1 (en) | Stable particle in liquid formulations | |
| EP0541556B1 (en) | Stabilization of biological macromolecular substances and other organic compounds | |
| AU710039B2 (en) | Compositions in glassy phase, stabilised by a sugar | |
| CN1160345A (en) | Improved method for stabilization of biological substances during drying and subsequent storage and compositions thereof | |
| EP2222315B1 (en) | Stabilized factor ix formulations containing trehalose | |
| JPH0853361A (en) | Freeze-dried formulations containing stable proteins and assay kits | |
| Iglesias et al. | Adsorption isotherm of amorphous trehalose | |
| EP0415567A2 (en) | Composition and method for stabilising organic compounds | |
| IE56173B1 (en) | Pharmacological cisplatinum compositions | |
| Pisal et al. | Vacuum foam drying for preservation of LaSota virus: effect of additives | |
| EP2552410B1 (en) | Method for preserving alum adjuvants and alum-adjuvanted vaccines | |
| CA2458794C (en) | Plasticized hydrophilic glasses for improved stabilization of biological agents | |
| AU4065393A (en) | Pharmaceutical compositions containing IL-6 | |
| AU690143B2 (en) | Stable lyophilized thiotepa composition | |
| CA2301889C (en) | Water-soluble dry compositions | |
| US20230144557A1 (en) | Method of long-term preservation of chemical and biological species using sugar glasses | |
| CN101991857B (en) | Stable pharmaceutical preparation and preparation method thereof | |
| EP1254944B1 (en) | Dry compositions containing hydrophobic amino acid | |
| EP0169700B1 (en) | Improved pharmaceutical formulations for ceftazidime | |
| Ashok et al. | Foam dried composite glass: An alternative to lyophilization for stability enhancement of bendamustine hydrochloride | |
| KR100857889B1 (en) | Dry ligase composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1999910516 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09623495 Country of ref document: US |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999910516 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1999910516 Country of ref document: EP |